Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disorder affecting hair follicles. Humira is the only FDA-approved therapy for the disease; its use is limited—based on the label—to patients with moderate to severe disease. In addition, a variety of therapies (e.g., antibiotics, hormonal agents, retinoids, corticosteroids) are prescribed off-label for HS. Alternative biologics may also be used off-label in patients with more-severe disease who do not respond to Humira (e.g., Janssen’s Stelara). The HS pipeline holds a diverse array of therapies with unique mechanisms of action, such as IL-17 inhibitors (Novartis’s Cosentyx), IL-23 inhibitors (AbbVie’s Skyrizi and Janssen’s Tremfya), IL-1 inhibitors (bermekimab), and JAK-1 inhibitors (INCB054707). If proven efficacious, these agents will enjoy huge commercial opportunity because of the immense unmet need in this space.
- · What are the key areas of unmet need and opportunity in the HS market?
- How are patients with different disease severities treated?
- What is the approximate size of the diagnosed prevalent and incident HS population in the United States? How are cases of HS segmented by severity?
- What is the expected impact of novel therapies?
- How does each current and future player influence the market, and how will their influence change in the future?
- What are the key drivers of and constraints on the HS therapy market?
United States Primary Research 3 KOL interviews in October 2019
Key COMPANIES Covered
AbbVie, Novartis, Janssen, XBiotech, Incyte
Key Drugs Covered
Humira, Cosentyx, Skyrizi, Tremfya, Remicade, Stelara, metformin, spironolactone, clindamycin, rifampicin, bermekimab, INCB054707
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Hidradenitis Suppurativa - Executive Insights - Executive Insights (US)
- Hidradenitis Suppurativa-Executive-Insights
Author(s): Ajay Puri, MBA
Ajay Puri is an Associate Analyst in the Immune and Inflammatory team at Decision Resources Group and works on indications like Ulcerative Colitis, Crohn’s disease, and Systemic Lupus Erythematosus.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA (Pharmaceutical) in marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Knowledge Management Associate (Oncology Vertical) at ZS Associates and worked on strategic projects such as competitive assessment, company and product profiling, conference coverage for clients, client specific newsletters and other business development initiatives.